CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial.

Nirali N. Shah,Steven L. Highfill,Haneen Shalabi,Bonnie Yates,J. Jin,Pamela L. Wolters,Amanda K. Ombrello,Seth M. Steinberg,Staci Martin,Cindy Delbrook,Leah Hoffman,Lauren Little,Anusha Ponduri,Haiying Qin,Haris Qureshi,Alina Dulau Florea,Dalia Salem,Hao-Wei Wang,Constance M. Yuan,Maryalice Stetler-Stevenson,Sandhya R. Panch,Minh Tran,Crystal L. Mackall,David F. Stroncek,Terry J. Fry

CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial.

2020

PURPOSEPatients with B-cell acute lymphoblastic leukemia who experience relapse after or are resistant to CD19-targeted immunotherapies have limited treatment options. Targeting CD22, an alternativ...

Keywords:

Pathology
T cell
Cell
Potency
Cytotoxic T cell
Medicine
Cancer research
CD22
CD22 CAR-T
Chimeric antigen receptor
Toxicity
car t cells

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations